AIM: To assess clinical utility of NMP22 Bladder Chek Test and to compare it with voided urine cytologyand cystoscopy in early detection of Bladder Cancer. Material &
Methods: A total of 115 patients of follow upcases of Bladder Cancer were enrolled in this study. Urine samples were assayed for the presence of NMP22using NMP22 Bladder Chek Test and Cytology was performed by a cytopathologist. The diagnosis, determinedfrom the Cystoscopic findings and biopsy findings of the suspicious lesion was considered as the gold standard.For positive biopsies, the results of the NMP22 Test and cytology were also correlated with tumour grade andstage.
Results: Mean age of the patients was 57.2 years for males and 55.3 years for females. A total of 59 casesof Bladder Cancer (TCC) were diagnosed among which NMP22 test was positive in 48 cases and cytology in26 cases. The sensitivity and specificities of NMP22 Test in recurrent bladder cases was 81.3% and 92% whichwas significantly greater than that of cytology 44% and 96.1% respectively. In non-invasive lesions of BladderCancer (TCC), NMP22 Test and Cytology was positive in 71.8% and 42.8% of cases respectively. In muscleinvasivelesions, NMP22 Test was positive in 82.2% and 44.4% cases were positive for cytology. The sensitivityof the NMP22 test was 81.3%, which was significantly greater than that of cytology 44%.
Conclusion: TheNMP22 Bladder Check is a new point of care diagnostic test for urinary bladder cancer. The results of our studyhave shown that the NMP22 can be used as a substitute for urine cytology as we detected high sensitivity andspecificity of NMP22 in recurrent bladder cases.